# InDevR

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indevr

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.indevr.com
- Total disclosed funding: $7M
- Latest round: Series A (Sep 10, 2019)
- Investors on record: 1

## About

InDevR, Inc. develops advanced analytical solutions for vaccine testing, focusing on optimizing development processes through their innovative VaxArray Platform for various vaccine types. Founded in 2003 and headquartered in Boulder, US, InDevR, Inc. specializes in analytical solutions for the biopharmaceutical sector. The company has not undergone significant strategic pivots and operates independently without known subsidiaries. The founding team, including CEO Ali Asghar and Kathy Rowlen, brings a wealth of industry experience. In January 2026, SSI Diagnostica A/S, a portfolio company of Adelis Equity, acquired InDevR, Inc. from Adjuvant Capital. Financial terms were not disclosed. InDevR specializes in providing innovative analytical solutions for vaccine testing, primarily through their flagship VaxArray Platform. This platform utilizes multiplex assay technology to deliver rapid and reliable analytical results, accommodating various assays in a single multiplex array. It serves multiple vaccine types, including mRNA, polysaccharide, conjugate, and viral vector vaccines, expediting development, optimization, and production processes. InDevR's offerings are designed for diverse stages of vaccine development, from research and development to clinical trials and product release testing. The company primarily serves biopharmaceutical companies, academic institutions, and research organizations in North America, Europe, and Asia, addressing the critical needs for quality control and compliance within the global regulatory landscape.InDevR generates revenue through direct business-to-business transactions with clients, typically in the biopharmaceutical and vaccine development sectors. The company offers both off-the-shelf and custom analytical solutions, allowing for tailored service options that meet specific client requirements. Transactions are structured around the sale of VaxArray assays and related services, with clients purchasing kits designed for specific vaccine testing needs. Due to the customized nature of its offerings, pricing plans are structured according to the complexity and scale of the services provided, ensuring clients receive efficient solutions tailored to their unique challenges. The firm’s revenue model reflects a commitment to providing high-quality, pre-validated assays that facilitate faster vaccine development timelines, particularly in response to evolving public health needs. InDevR plans to leverage its recent funding to enhance its product offerings and expand market reach. Upcoming product developments are focused on new multiplex assays that will be released in the next 18 months, aiming to facilitate broader vaccine testing applications. The company is targeting expansion into emerging markets in Asia and South America, capitalizing on the growing demand for advanced vaccine testing solutions in these regions.

## Funding rounds

- Series A, Sep 10, 2019, $7M — Adjuvant Capital

## Investors

- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A